多西紫杉醇联合顺铂同步放化疗治疗中晚期宫颈癌的临床疗效及不良反应

Clinical efficacy and adverse reaction of docetaxel combined cisplatin in concurrent radiotherapy and chemotherapy for advanced cervical cancer

目的分析多西紫杉醇联合顺铂同步放化疗治疗中晚期宫颈癌的临床疗效及不良反应。方法将174例宫颈癌患者根据治疗方法的不同分为观察组(n=88,多西紫杉醇联合顺铂)与对照组(紫杉醇联合顺铂)。比较两组疗效、不良反应及免疫功能指标。结果观察组患者疾病控制率高于对照组,差异有统计学意义(P<0.05)。对照组患者消化道反应、骨髓抑制发生率均高于观察组,差异均有统计学意义(P<0.05)。治疗后,两组患者CD4^(+)、CD4^(+)/CD8^(+)均较治疗前升高,CD8^(+)均较治疗前降低,且观察组患者CD4^(+)、CD4^(+)/CD8^(+)均高于对照组,CD8^(+)低于对照组,差异均有统计学意义(P<0.05)。结论多西紫杉醇联合顺铂同步放化疗治疗中晚期宫颈癌的临床疗效确切,可减少患者不良反应,改善其免疫功能。

Objective To analyze the clinical efficacy and adverse reaction of docetaxel combined cisplatin in concurrent radiotherapy and chemotherapy for advanced cervical cancer.Method A total of 174 patients with cervical cancer were selected and divided into the observation group(n=88,treated with docetaxel+cisplatin)and control group(n=86,treated with paclitaxel+cisplatin)according to different treatment.The clinical efficacy,adverse reaction and immunity function indexes were compared.Result The disease control rate of the observation group was higher than that of the control group(P<0.05).The incidence of digestive tract reaction and bone marrow suppression in the control group were higher than those in the observation group(P<0.05).After treatment,CD4^(+),CD4^(+)/CD8^(+)of the two groups were increased and CD8^(+)was decreased compared with those before treatment,with higher CD4^(+),CD4^(+)/CD8^(+)and lower CD8^(+)in observation group than those in the control group(P<0.05).Conclusion Docetaxel+cisplatin in concurrent radiotherapy and chemotherapy has a definite clinical effect in the treatment of advanced cervical cancer,which can reduce the adverse reaction of patients and improve the immune function.